home / stock / mrus / mrus news

MRUS News and Press, Merus N.V. From 01/07/21

Stock Information
Company Name: Merus N.V.
Stock Symbol: MRUS
Market: NASDAQ
Website: merus.nl
Menu
MRUS MRUS Quote MRUS Short MRUS News MRUS Articles MRUS Message Board
Get MRUS Alerts

News, Short Squeeze, Breakout and More Instantly...
MRUS - Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™) for cancer, today announced that the U....
MRUS - Merus rises 4% on Incyte stake disclosure

Merus (MRUS) gains 4% premarket after Incyte (INCY) reports 11% stake or holding of 3.2M shares of the company. The company had 29.09M common shares as of Oct. 30, 2020.Pursuant to the Subscription Agreement, on January 23, 2017, Incyte purchased an aggregate of 3.2M common shares a...

MRUS - Merus and Sema4 Enter Into an Agreement to Support Merus' Phase 1/2 Clinical Trial of Zenocutuzumab

UTRECHT, The Netherlands and STAMFORD, Conn., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multi-specific antibodies (Biclonics® and Triclonics TM ), and Sem a 4 , a patient-centere...

MRUS - Merus to Present at the Jefferies Virtual London Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that B...
MRUS - Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific ant...

MRUS - Merus EPS misses by $0.07, beats on revenue

Merus (MRUS): Q3 GAAP EPS of -$0.64 misses by $0.07.Revenue of $8.57M (+5.0% Y/Y) beats by $1.12M.Cash, cash equivalents and marketable securities of $190.2M.Press Release For further details see: Merus EPS misses by $0.07, beats on revenue

MRUS - Merus Announces Financial Results for the Third Quarter and Provides Business Update

– Clinical data and program update planned for lead program Zenocutuzumab (“Zeno”) in 2Q 2021 – – MCLA-129 expected to enter clinic in 2021 – UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Merus N...
MRUS - Merus and myTomorrows expand partnership for eNRGy trial awareness for patients with NRG1 tumors

Merus (MRUS) and myTomorrows, a global health technology company have expanded their ongoing collaboration to raise awareness of screening opportunities for and recruitment of patients with neuregulin 1 (NRG1) fusion cancers. Under a 2019 agreement, myTomorrows has been successfully prov...

MRUS - Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonic...

MRUS - 4 DOWNGRADED Stocks That Aren't Worth the Risk

Youdao (DAO), Avrobio (AVRO), Merus (MRUS), and PrimeEnergy (PNRG) are four stocks recently downgraded by the POWR Ratings. If the market decline resumes, it's likely that these stocks will lead to the downside. The latest POWR Ratings  have arrived. A wide array of stocks w...
Previous 10 Next 10